Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA127 for chemotherapy-induced thrombocytopenia in ovarian cancer
NCT00771810Phase 2Completed
- Sponsor
- Tarix Pharmaceuticals Ltd.
- Start
- Oct 2008
- Primary completion
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of talfirastide in Thrombocytopenia (3 arms), sponsored by Tarix Pharmaceuticals Ltd. Primary endpoint: Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3. Started Oct 2008; status: completed.
02
Drugs
talfirastide
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00771810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771810.